Revenue of $716.0 million in the third quarter of 2026 increased 8.5% from revenue of $659.9 million for the comparable prior ...
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, ...
Kardium today announced the first site activation and first patient enrollment in the Globe Registry: Globe ® Pulsed Field ...
Jefferies, Leerink Partners and TD Cowen are acting as joint book-running managers.
HEADSTART-ACS study conducted in collaboration with Indonesia’s National Cardiovascular Center in world’s fourth most ...
Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in ...
Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and ...
Collaboration to explore how AI-facilitated technology can help make patient support programs more individualized, responsive ...
HIV treatment, Cabenuva, with a median treatment duration of 18 months Among individuals switching to Cabenuva, 94% had a ...
Company to host conference call and webcast on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time SAN DIEGO--(BUSINESS ...
The $100,000 H-1B visa fee has significantly affected who biopharma companies hire, according to two experts. It’s not the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results